Evidence map›Paper›PMID 42185390›Full record

ArticleScientific reports2026

Efficient and metal catalyst-free approach towards highly-substituted N-sulfonylpiperidine-/mono-spiro-1,2,4,5-tetraoxanes for potential applications in chemotherapy.

Mohit K Tiwari, Malgorzata Kucinska, Agnieszka Zgoła-Grześkowiak, Philippe Grellier, Marek Murias, Łukasz Marczak, Lukasz Popenda, Tomasz Goslinski

Abstract read
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Mohit K TiwariChair and Department of Chemical Technology of Drugs, Poznan University of Medical Sciences, Rokietnicka 3, 60-806, Poznan, Poland. mtiwari@ump.edu.pl.
Malgorzata KucinskaChair and Department of Toxicology, Poznan University of Medical Sciences, Rokietnicka 3, 60-806, Poznan, Poland.
Agnieszka Zgoła-GrześkowiakInstitute of Chemistry and Technical Electrochemistry, Poznan University of Technology, Berdychowo 4, 60-965, Poznan, Poland.
Philippe GrellierUMR7245 MCAM, CNRS, National Museum of Natural History, CP 52, 57 Rue Cuvier, 75005, Paris, France.
Marek MuriasChair and Department of Toxicology, Poznan University of Medical Sciences, Rokietnicka 3, 60-806, Poznan, Poland.
Łukasz MarczakInstitute of Bioorganic Chemistry, Polish Academy of Sciences, Noskowskiego 12/14, 61-704, Poznan, Poland.
Lukasz PopendaNanoBioMedical Centre, Adam Mickiewicz University, Wszechnicy Piastowskiej 3, 61-614, Poznan, Poland.
Tomasz GoslinskiChair and Department of Chemical Technology of Drugs, Poznan University of Medical Sciences, Rokietnicka 3, 60-806, Poznan, Poland.

Funding

National Science Centre, Poland 2023/48/C/NZ7/00036
6 · The paper itself

Abstract

A highly efficient metal and catalyst-free approach for the preparation of synthetically challenged tri-OMe-aryl-substituted heterocyclic, di-/tri-OMe-aryl-based cyclic and acyclic 1,2,4,5-tetraoxanes (5a-l and 6a-k) is presented herein. Under green-chemistry conditions, the reactions occur in two key steps. The first one involves azeotropic activation of hydrogen peroxide for N-sulfonylpiperidone (2a-f), substituted cyclic and acyclic ketones (2a

Indexed as

Antineoplastic AgentsPiperidinesTetraoxanesCatalysisCell Line, TumorCyclizationHumansOxidation-ReductionPlasmodium falciparumAntineoplastic AgentsPiperidinesTetraoxanesAntiplasmodial activityCytotoxicityMetal-free reactionTetraoxanes

Identifiers

PMID42185390
PMCPMC13434043

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.